SCHEMBL1179458

SCHEMBL1179458

CCCc1cc(C(=O)OCC)nc(SC)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
TSHR P16473 4/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 2/20 0.44
ADORA3 P0DMS8 2/20 0.41
ADORA2A P29274 2/20 0.41
ALDH1A1 P00352 6/20 0.40
MAPK1 P28482 2/20 0.40
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179686 0.88 CYP1A2 (0.46) MAPTTSHRLMNACYP1A2ALDH1A1
SCHEMBL1178986 0.83 MAPT (0.43) MAPTTSHRLMNACYP1A2ALDH1A1
SCHEMBL5010959 0.82 MAPT (0.58) MAPTTSHRLMNACYP1A2ALDH1A1
SCHEMBL8550932 0.79 CYP1A2 (0.46) MAPTTSHRLMNACYP1A2ALDH1A1
SCHEMBL31620656 0.77 MAPT (0.44) MAPTTSHRLMNACYP1A2ALDH1A1
SCHEMBL1179066 0.76 ALDH1A1 (0.45) MAPTLMNACYP1A2ALDH1A1MAPK1
SCHEMBL6989832 0.72 CYP1A2 (0.56) MAPTTSHRLMNACYP1A2ALDH1A1
SCHEMBL4444475 0.72 BACE1 (0.39) MAPTCYP1A2ADORA3ADORA2AALDH1A1
SCHEMBL1179463 0.70 CA12 (0.50) MAPTTSHRLMNACYP1A2MEN1
SCHEMBL9993619 0.70 CYP1A2 (0.72) MAPTTSHRLMNACYP1A2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD MAPT 3934/4885TSHR 3634/4885LMNA 4595/4885
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 MAPT 3786/4885TSHR 2962/4885LMNA 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.